You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKesson
Dow
Mallinckrodt
Boehringer Ingelheim

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 10,052,381

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,052,381
Title:Classifiers of NF-.kappa.B pathway activation, devices, and methods of use thereof
Abstract: This disclosure relates to classifiers of NF-.kappa.B pathway activation, devices, and methods of use thereof. In certain embodiments, the disclosure relates to methods comprising measuring changes in expression of genes controlled by p105 in a sample providing a detected p105 controlled gene expression pattern. In certain embodiments, the methods further comprise measuring changes in expression of genes controlled by p100 in a sample providing a detected p100 controlled gene expression pattern. In certain embodiments, the methods further comprise the step of comparing the detected p105 controlled gene expression patterns to a predetermined gene pattern and/or the detected p100 controlled gene expression patterns to a predetermined pattern.
Inventor(s): Bernal-Mizrachi; Leon (Atlanta, GA)
Assignee: Emory University (Atlanta, GA)
Application Number:15/482,353
Patent Claims:see list of patent claims

Details for Patent 10,052,381

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Emory University (Atlanta, GA) 2032-09-20 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Emory University (Atlanta, GA) 2032-09-20 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Emory University (Atlanta, GA) 2032-09-20 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Emory University (Atlanta, GA) 2032-09-20 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
AstraZeneca
Johnson and Johnson
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.